Home/Pipeline/Transdermal Treprostinil Prodrug Patch

Transdermal Treprostinil Prodrug Patch

Pulmonary Arterial Hypertension (PAH)

Pre-clinicalActive

Key Facts

Indication

Pulmonary Arterial Hypertension (PAH)

Phase

Pre-clinical

Status

Active

Company

Corsair Pharma

About Corsair Pharma

Corsair Pharma is a private, pre-revenue biotech founded in 2018, headquartered in Cambridge, USA, developing an improved transdermal therapy for pulmonary arterial hypertension (PAH). Its lead candidate is a proprietary patch delivering a prodrug of treprostinil, designed to offer consistent drug levels without the burdens and side effects of current infusion pumps. With a strategic partnership with United Therapeutics and plans to initiate a Phase 1 trial in late 2024, Corsair is targeting a significant unmet need in an orphan disease market dominated by complex, invasive therapies.

View full company profile

Therapeutic Areas

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension

Other Pulmonary Arterial Hypertension (PAH) Drugs

Drug	Company	Phase	Status
YUTREPIA™ (treprostinil) inhalation powder	Liquidia	Approved	Commercial
LIQ861 (treprostinil) inhalation powder	Liquidia	Phase 3	Completed
L606 (liposomal treprostinil) injection	Liquidia	Preclinical	Active
NTP42	ATXA Therapeutics	Phase 1	Active; Orphan Drug Designation from FDA and EMA. Phase 1 results published.
Anti-EMAP II monoclonal antibody	Allinaire Therapeutics	Pre-clinical	Active
Tiprelestat	tiakis Biotech	Phase 2	Active
Seralutinib	Chiesi	Phase 3	Active
Sotatercept	Merck	Phase 3	Active
TPIP (Treprostinil Palmitil Inhalation Powder)	Insmed	Phase 2b	Active
Ralinepag	United Therapeutics	Phase 3	Active (ADVANCE CAP)
Beraprost MR	United Therapeutics	Phase 3	Active (ISABELA)
CS1	Cereno Scientific	Phase II	Active; Phase IIa completed, Phase IIb in preparation